<DOC>
	<DOCNO>NCT01983748</DOCNO>
	<brief_summary>Patients suffer uveal melanoma ( typed positive monosomy 3 ) vaccinate period 2 year Dendritic Cell load autologous Tumor RNA . 200 patient include . The Trial open multicenter Phase III Trial .</brief_summary>
	<brief_title>Dendritic Cells Plus Autologous Tumor RNA Uveal Melanoma</brief_title>
	<detailed_description>Trial arm A ( DCaT-RNA ) = Experimental intervention : Patients arm A receive 8 vaccination period 2 year consist autologous , mature , monocyte-derived Dendritic Cells load autologous tumor RNA ( 20 mio DC per vaccination ) ; cell give via intravenous infusion ; vaccination follow 1 year observation ( stag every 3 month ) Trial arm B ( Observation ) = Control : Patients arm B receive standard care ( observation stag every 3 month )</detailed_description>
	<mesh_term>Melanoma</mesh_term>
	<mesh_term>Uveal Neoplasms</mesh_term>
	<mesh_term>Monosomy</mesh_term>
	<criteria>Patients must suffer melanoma uvea ( stage T2 , T3 T4 [ AJCC TNM grade 2009 ] ) . Uveal melanoma must resect display monosomy chromosome 3 ( determine validate qualitative analysis loss heterozygosity ) . Tumor material store appropriately RNAlater solution RNA preparation . The patient free detectable tumor time point study enrollment ( adjuvant setting ) , assess clinical inspection , abdominal sonography , chest Xray evaluation tumormarker S100.. Patients must WHO performance status 0 , 1 2 must stable medical condition . Patients must 18 75 year old must able willing give inform consent . Women childbearing age must negative pregnancy test , must oblige use effective contraception least 4 week last vaccination . Patients must willing get hospitalize least 4 hour follow vaccination ( ) , cooperate whole period trial . Patients must fully recover surgery . Signed informed consent Any major serious illness [ e.g . active systemic infection , immunodeficiency disease , clinically significant heart disease , respiratory disease , bleed disorder , cancer etc . ] contraindication leukapheresis . Evidence HIV1 , HIV 2 , HTLV1 , HBV , HCV infection . Active autoimmune disease ( limited Lupus erythematosus , autoimmune thyroiditis uveitis , multiple sclerosis , inflammatory bowel disease ) . Vitiligo pathological laboratory result ( autoantibody ) without clinical symptom , however , exclusion criterion . Previous splenectomy radiation therapy spleen . Patients organ allograft . Concomitant treatment chemotherapy , immunotherapy , investigational drug paramedical substance . Patients may receive concomitant medication control symptoms analgetics , antihypertensive medication , etc . History active malignant neoplasm within precede 5 year ( exclude nonmelanoma skin cancer carcinoma situ cervix ) . Organic brain syndrome significant psychiatric abnormality would impede informed consent / AND preclude participation full protocol follow . Positive pregnancy test / Pregnancy lactation . If pregnancy occur course trial female patient arm A B , patient exclude . Detection metastasis . If uveal melanoma metastasis appear course trial , patient exclude . Lack compliance patient .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>December 2015</verification_date>
	<keyword>Uveal Melanoma , Monosomy 3</keyword>
</DOC>